Bacterieel intracerebraal absces
Uitgangsvraag
The epidemiology of bacterial intracerebral abscess in Europe/US.
Aanbeveling
Empirical treatment for bacterial cerebral abscesses consists of a third generation cephalosporin (ceftriaxone or cefotaxime) combined with metronidazole in appropriate doses to penetrate the blood brain barrier (Table 1 under summary literature). Alternatively, penicillin may be used instead of a third generation cephalosporin.
If a microorganism is cultured, therapy can be adjusted accordingly. In culture-negative cases the empirical therapy should be continued until clinical resolution.
The common strategy for antibiotic treatment of cerebral abscesses is to treat the abscess at least 6 weeks and to use clinical, laboratory and radiological follow-up data to decide on further treatment beyond this period.
Overwegingen
For this module no considerations have been formulated.
Onderbouwing
Conclusies
* |
No clinical trials have been performed to determine the optimal antibiotic treatment in bacterial intracerebral abscesses, |
Samenvatting literatuur
What is the epidemiology of bacterial intracerebral abscess in Europe/US?
We identified 51 studies reporting bacterial causes of brain abscesses that met the inclusion criteria.63-112,113 In these studies 3,583 patients were included (table 2). In 2536 patients (71%) data on bacterial cultures were provided, and in 435 patients no culture was performed (17%). Cultures were negative in 30% and in studies reporting the number of cultured bacteria, 26% of the cultures were polymicrobial. This may be an underestimation as local microbiology data suggest that the rate of polymicrobial intracranial abscesses may be as high as 50%.
Of the 2,653 bacteria cultured in the included studies, Streptococcus species were the most prevalent and were identified in 36% of the positive cultures (table 3). Specification of streptococcal species was not available for the majority of strains. Streptococci from the milleri group were the most frequently identified species, occurring in 9% of all patients and 72% of specified streptococcal species. S. pneumoniae, the most frequent pathogen of bacterial meningitis, was identified in only 3% of all positive cultures in brain abscess patients.6 The second most common microorganisms identified in brain abscesses were Staphylococcus species (frequency 17%). Staphylococcus aureus was identified in 11% of patients and Staphylococcus epidermidis in 2%. The species were not specified of the remaining strains. Gram negative enteric bacteria were found in 12% of cases and most of these were Proteus spp. (7%). Other relatively frequent pathogens were Bacteroides spp. (7%), Haemophilus spp (3%) and Peptostreptococcus spp (3%). In these included studies 17% of bacteria were classified as ‘other’ or were not specified.
Anaerobe bacteria are present in virtually all polymicrobial abscesses and are frequently found in cerebral abscesses with a dentogenic focus. The frequency of anaerobes given in Supplementary table 3 may be an underestimation due to suboptimal culture techniques and transportation.
16S ribosomal DNA sequencing has expanded the yield of microbiological investigation in patients with intracerebral abscesses.114 The number of causative pathogens identified by sequencing of brain abscess aspirate was over threefold higher compared to standard culture techniques (22 strains identified by culture vs. 72 by sequencing).114 This technique is currently not commonly used, but will probably become part of routine diagnostics in the coming years.
What is the optimal (empirical) antibiotic therapy in intracerebral abscess?
No clinical trials have been performed to determine the optimal regimen in bacterial intracerebral abscesses, therefore the recommendations are all based on expert opinion.8,9 Empirical treatment consists of a third generation cephalosporin (ceftriaxone or cefotaxime) combined with metronidazole in appropriate doses to penetrate the blood brain barrier. Alternatively penicillin may be used instead of third generation cephalosporins. After identification of the causative microorganism the antimicrobial therapy can be adapted according to the antimicrobial resistance pattern. In culture-negative cases the empirical therapy should be continued until clinical resolution (see question "What is the optimal duration of therapy?").
The primary source of infection can give a clue to which bacteria cause the cerebral abscesses. For instance, Enterobacteriaceae are the most frequently found in cerebral abscesses due to otogenic infections. However, since virtually all common pathogens have been reported for the various sources of infection, the choice of empirical antimicrobial therapy cannot be guided by the source of infection (e.g. dental abscess, endocarditis).
What is the optimal dose of antimicrobial therapy?
Only a limited number of antimicrobials have been studied for their penetration into brain abscesses, mostly in small studies.53Antimicrobials have to be able to first penetrate the blood brain barrier and then to achieve sufficient levels inside the abscess to resolve the infection. Penicillin concentrations were only found consistently in brain abscess pus if administered in a high dose of 24 million units per day.115Commonly advised doses of penicillin are however 12 million units per day in adults.8,9 Other antimicrobials that have shown adequate or good penetration into the abscess cavity are metronidazole, vancomycin and third generation cephalosporins.53 The dosage and dose intervals of antimicrobials commonly used for brain abscesses are presented in table 1. For vancomycin and aminoglycosides, the dose needs to be adjusted according to the peak and trough serum concentrations.
Table 1 Dosages of antibiotics for use in adults with bacterial brain abscesses.a
Antibiotic |
Total daily dose |
Dose interval (hour) |
Amikacinb |
15 mg/kg |
24 |
Amoxicillin |
12 gr |
4 |
Azitromycin |
1200-1500 mg |
24 |
Cefotaxime |
8-12 gr |
4-6 |
Ceftazidime |
6 gr |
8 |
Ceftriaxone |
4 gr |
12 |
Chloramphenicol |
4-6 gr or 50 mg/kg/day |
6 |
Ciprofloxacin |
800-1200 mg |
8-12 |
Clindamycin |
2400-4800 mg |
6 |
Gentamicinb |
5 mg/kg |
24 |
Meropenem |
6 gr |
8 |
Metronidazol |
1500 mg |
8 |
Penicillin |
12x106 units |
4 (or continuous) |
Rifampicin |
600 |
24 |
Tobramycin b |
5 mg/kg |
24 |
Trimethoprim-sulfamethoxazole (TMP/SMX) |
10-20 mg/kg iv (based on TMP component), max. 960/4800 mg TMP/SMX iv |
8 8 |
Vancomycinb |
30-45 mg/kg, max. 2000 mg |
12 |
Adapted from8. aPatients with normal hepatic and renal function, intravenous administration. bAdjust dosage based on peak and trough serum concentrations.
What is the optimal duration of therapy?
No studies have been performed to evaluate the optimal duration of therapy in bacterial brain abscesses. The common strategy is to treat the abscess at least 6 weeks and to use clinical, laboratory and radiological follow-up data to decide on further treatment beyond this period.8,9 Studies on antimicrobial treatment duration for cerebral abscesses are needed.
Table 2 Culture results presented in 51 studies on intracerebral abscesses including 3583 patients.
Characteristics |
n/N (%) |
Culture data specified |
2536/3583 (71%) |
Culture not performed |
435/2536 (17%) |
Positive culture |
1478/2101 (70%) |
Monomicrobial |
1083/1457 (74%) |
Polymicrobial |
374/1457 (26%) |
Negative culture |
623/2101 (30%)
|
Table 3
Bacteria |
No (%) |
|
|
Staphylococcus spp |
454 (17.1%) |
Staphylococcus aureus |
292 (11.0%) |
Staphylococcus epidermidis |
62 (2.3%) |
Staphylococciother/not specified |
100 (3.8%) |
Streptococcus spp |
953 (35.9%) |
Aerobic streptococci |
39 (1.5%) |
Haemolytic streptococci |
34 (1.3%) |
Anhaemolytic streptococci |
27 (1.0%) |
Streptococcus milleri/ viridans streptococci |
219 (8.3%) |
Microaerophilicstreptococci |
55 (2.1%) |
Streptococcus pneumoniae |
72 (2.7%) |
Streptococcus other/not specified |
397 (15.0%) |
Gram negative enteric rods |
313 (11.8%) |
Escherichia coli |
42 (1.6%) |
Klebsiella spp |
30 (1.1%) |
Proteus spp |
183 (6.9%) |
Other Gram-negative enteric rods |
58 (2.2%) |
Pseudomonas spp |
47 (1,8%) |
Haemophilus spp |
85 (3.2%) |
Actinomycetales |
80 (3.0%) |
Nocardia |
14 (0.5%) |
Actinomyces |
25 (0.9%) |
Corynebacterium |
29 (1.1%) |
Other Actinomycetales |
20 (0.8%) |
Peptostreptoccus spp |
88 (3.3%) |
Anaerobic streptococci |
71 (2.7%) |
Bacteroides spp |
181 (6.8%) |
Other |
199 (7.5%) |
Not specified |
253 (9.5%)
|
Referenties
- van de Beek D, Weisfelt M, de Gans J, Tunkel AR, Wijdicks EF. Drug Insight: adjunctive therapies in adults with bacterial meningitis. Nat Clin Pract Neurol 2006; 2: 504-16.
- van de Beek D, Brouwer MC, de Gans J et al. Richtlijn bacteriele meningitis. Utrecht: Nederlandse Vereniging voor Neurologie; 2011.
- van de Beek D, Drake JM, Tunkel AR. Nosocomial bacterial meningitis. N Engl J Med 2010; 362: 146-54.
- Bohr V, Rasmussen N, Hansen B et al. 875 cases of bacterial meningitis: diagnostic procedures and the impact of preadmission antibiotic therapy. Part III of a three-part series. J Infect 1983; 7: 193-202.
- Brouwer MC, Tunkel AR, van de Beek D. Epidemiology, diagnosis, and antimicrobial treatment of acute bacterial meningitis. Clin Microbiol Rev 2010; 23: 467-92.
- Spanos A, Harrell FE, Jr., Durack DT. Differential diagnosis of acute meningitis. An analysis of the predictive value of initial observations. JAMA 1989; 262: 2700-7.
- Tunkel AR. Brain abscess. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and practive of infectious diseases. 7 ed. Philadelphia: Churchill livingstone; 2010. p. 1265-78.
- Kastenbauer S, Pfister HW, Wispelwey B, Scheld WM. Brain abscess. In: Scheld WM, Whitley RJ, Marra CM, editors. Infections of the central nervous system. 3 ed. Philadelphia: Lippincott Williams & Wilkins; 2004. p. 479-507.
- van de Beek D, de Gans J, Spanjaard L, Weisfelt M, Reitsma JB, Vermeulen M. Clinical features and prognostic factors in adults with bacterial meningitis. N Engl J Med 2004; 351: 1849-59.
- Brouwer MC, Heckenberg SG, de GJ, Spanjaard L, Reitsma JB, van de Beek D. Nationwide implementation of adjunctive dexamethasone therapy for pneumococcal meningitis. Neurology 2010.
- van de Beek D, de Gans J, Tunkel AR, Wijdicks EF. Community-acquired bacterial meningitis in adults. N Engl J Med 2006; 354: 44-53.
- Garges HP, Moody MA, Cotten CM et al. Neonatal meningitis: what is the correlation among cerebrospinal fluid cultures, blood cultures, and cerebrospinal fluid parameters? Pediatrics 2006; 117: 1094-100.
- Hristeva L, Booy R, Bowler I, Wilkinson AR. Prospective surveillance of neonatal meningitis. Arch Dis Child 1993; 69: 14-8.
- Holt DE, Halket S, de LJ, Harvey D. Neonatal meningitis in England and Wales: 10 years on. Arch Dis Child Fetal Neonatal Ed 2001; 84: F85-F89.
- Galiza EP, Heath PT. Improving the outcome of neonatal meningitis. Curr Opin Infect Dis 2009; 22: 229-34.
- Heath PT, Nik Yusoff NK, Baker CJ. Neonatal meningitis. Arch Dis Child Fetal Neonatal Ed 2003; 88: F173-F178.
- Siegal T, Pfeffer MR, Steiner I. Antibiotic therapy for infected Ommaya reservoir systems. Neurosurgery 1988; 22: 97-100.
- Cooper MD, Keeney RE, Lyons SF, Cheatle EL. Synergistic effects of ampicillin-aminoglycoside combinations on group B streptococci. Antimicrob Agents Chemother 1979; 15: 484-6.
- Netherlands Reference Laboratory for Bacterial Meningitis (AMC/RIVM). Bacterial meningitis in the Netherlands Annual report 2010. Amsterdam: University of Amsterdam; 2011.
- Odio CM, Puig JR, Feris JM et al. Prospective, randomized, investigator-blinded study of the efficacy and safety of meropenem vs. cefotaxime therapy in bacterial meningitis in children. Meropenem Meningitis Study Group. Pediatr Infect Dis J 1999; 18: 581-90.
- Brouwer MC, Heckenberg SG, de Gans J, Spanjaard L, Reitsma JB, van de Beek D. Nationwide implementation of adjunctive dexamethasone therapy for pneumococcal meningitis. Neurology 2010; 75: 1533-9.
- Heckenberg SG, de Gans J, Brouwer MC et al. Clinical features, outcome, and meningococcal genotype in 258 adults with meningococcal meningitis: a prospective cohort study. Medicine (Baltimore) 2008; 87: 185-92.
- Brouwer MC, van de Beek D, Heckenberg SG, Spanjaard L, de Gans J. Community-acquired Listeria monocytogenes meningitis in adults. Clin Infect Dis 2006; 43: 1233-8.
- Karageorgopoulos DE, Valkimadi PE, Kapaskelis A, Rafailidis PI, Falagas ME. Short versus long duration of antibiotic therapy for bacterial meningitis: a meta-analysis of randomised controlled trials in children. Arch Dis Child 2009; 94: 607-14.
- van de Beek D, Brouwer MC. No difference between short-course and long-course antibiotics for bacterial meningitis in children, but available evidence limited. Evid Based Med 2010; 15: 6-7.
- Molyneux E, Nizami SQ, Saha S et al. 5 versus 10 days of treatment with ceftriaxone for bacterial meningitis in children: a double-blind randomised equivalence study. Lancet 2011; 377: 1837-45.
- Tunkel AR, Hartman BJ, Kaplan SL et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis 2004; 39: 1267-84.
- van der Meer H, van ZA, Spanjaard L, Van FM. [An infant with meningitis caused by resistant pneumococcus: infection despite vaccination]. Ned Tijdschr Geneeskd 2012; 156: A3806.
- Mitja O, Pigrau C, Ruiz I et al. Predictors of mortality and impact of aminoglycosides on outcome in listeriosis in a retrospective cohort study. J Antimicrob Chemother 2009; 64: 416-23.
- Lorber B. Listeriosis. Clin Infect Dis 1997; 24: 1-9.
- Red Book: 2009 report of the committee on infectious diseases. 28 ed. Elk Grove Village, IL, USA: American Academy of Pediatrics; 2009.
- Falagas ME, Bliziotis IA, Tam VH. Intraventricular or intrathecal use of polymyxins in patients with Gram-negative meningitis: a systematic review of the available evidence. Int J Antimicrob Agents 2007; 29: 9-25.
- Lozier AP, Sciacca RR, Romagnoli MF, Connolly ES, Jr. Ventriculostomy-related infections: a critical review of the literature. Neurosurgery 2008; 62 Suppl 2: 688-700.
- Mayhall CG, Archer NH, Lamb VA et al. Ventriculostomy-related infections. A prospective epidemiologic study. N Engl J Med 1984; 310: 553-9.
- Stenager E, Gerner-Smidt P, Kock-Jensen C. Ventriculostomy-related infections--an epidemiological study. Acta Neurochir (Wien ) 1986; 83: 20-3.
- Coplin WM, Avellino AM, Kim DK, Winn HR, Grady MS. Bacterial meningitis associated with lumbar drains: a retrospective cohort study. J Neurol Neurosurg Psychiatry 1999; 67: 468-73.
- Lyke KE, Obasanjo OO, Williams MA, O'Brien M, Chotani R, Perl TM. Ventriculitis complicating use of intraventricular catheters in adult neurosurgical patients. Clin Infect Dis 2001; 33: 2028-33.
- Wong GK, Poon WS, Wai S, Yu LM, Lyon D, Lam JM. Failure of regular external ventricular drain exchange to reduce cerebrospinal fluid infection: result of a randomised controlled trial. J Neurol Neurosurg Psychiatry 2002; 73: 759-61.
- Pfisterer W, Muhlbauer M, Czech T, Reinprecht A. Early diagnosis of external ventricular drainage infection: results of a prospective study. J Neurol Neurosurg Psychiatry 2003; 74: 929-32.
- Park P, Garton HJ, Kocan MJ, Thompson BG. Risk of infection with prolonged ventricular catheterization. Neurosurgery 2004; 55: 594-9.
- Arabi Y, Memish ZA, Balkhy HH et al. Ventriculostomy-associated infections: incidence and risk factors. Am J Infect Control 2005; 33: 137-43.
- Schade RP, Schinkel J, Visser LG, Van Dijk JM, Voormolen JH, Kuijper EJ. Bacterial meningitis caused by the use of ventricular or lumbar cerebrospinal fluid catheters. J Neurosurg 2005; 102: 229-34.
- Ohrstrom JK, Skou JK, Ejlertsen T, Kosteljanetz M. Infected ventriculostomy: bacteriology and treatment. Acta Neurochir (Wien ) 1989; 100: 67-9.
- Vinchon M, Dhellemmes P. Cerebrospinal fluid shunt infection: risk factors and long-term follow-up. Childs Nerv Syst 2006; 22: 692-7.
- Conen A, Walti LN, Merlo A, Fluckiger U, Battegay M, Trampuz A. Characteristics and treatment outcome of cerebrospinal fluid shunt-associated infections in adults: a retrospective analysis over an 11year period. Clin Infect Dis 2008; 47: 73-82.
- Walters BC, Hoffman HJ, Hendrick EB, Humphreys RP. Cerebrospinal fluid shunt infection. Influences on initial management and subsequent outcome. J Neurosurg 1984; 60: 1014-21.
- Filka J, Huttova M, Tuharsky J, Sagat T, Kralinsky K, Krcmery V, Jr. Nosocomial meningitis in children after ventriculoperitoneal shunt insertion. Acta Paediatr 1999; 88: 576-8.
- Kestle JR, Garton HJ, Whitehead WE et al. Management of shunt infections: a multicenter pilot study. J Neurosurg 2006; 105: 177-81.
- Sacar S, Turgut H, Toprak S et al. A retrospective study of central nervous system shunt infections diagnosed in a university hospital during a 4-year period. BMC Infect Dis 2006; 6:43.: 43.
- Korinek AM, Baugnon T, Golmard JL, van Effenterre R, Coriat P, Puybasset L. Risk factors for adult nosocomial meningitis after craniotomy: role of antibiotic prophylaxis. Neurosurgery 2008; 62 Suppl 2: 532-9.
- McClelland S, III, Hall WA. Postoperative central nervous system infection: incidence and associated factors in 2111 neurosurgical procedures. Clin Infect Dis 2007; 45: 55-9.
- Aucoin PJ, Kotilainen HR, Gantz NM, Davidson R, Kellogg P, Stone B. Intracranial pressure monitors. Epidemiologic study of risk factors and infections. Am J Med 1986; 80: 369-76.
- Kourbeti IS, Jacobs AV, Koslow M, Karabetsos D, Holzman RS. Risk factors associated with postcraniotomy meningitis. Neurosurgery 2007; 60: 317-25.
- Federico G, Tumbarello M, Spanu T et al. Risk factors and prognostic indicators of bacterial meningitis in a cohort of 3580 postneurosurgical patients. Scand J Infect Dis 2001; 33: 533-7.
- Wang KW, Chang WN, Huang CR et al. Post-neurosurgical nosocomial bacterial meningitis in adults: microbiology, clinical features, and outcomes. J Clin Neurosci 2005; 12: 647-50.
- Zarrouk V, Vassor I, Bert F et al. Evaluation of the management of postoperative aseptic meningitis. Clin Infect Dis 2007; 44: 1555-9.
- Baltas I, Tsoulfa S, Sakellariou P, Vogas V, Fylaktakis M, Kondodimou A. Posttraumatic meningitis: bacteriology, hydrocephalus, and outcome. Neurosurgery 1994; 35: 422-6.
- Infection in neurosurgery working party of the british society for antimicrobial chemotherapy. The management of neurosurgical patients with postoperative bacterial or aseptic meningitis or external ventricular drain-associated ventriculitis. Infection in Neurosurgery Working Party of the British Society for Antimicrobial Chemotherapy. Br J Neurosurg 2000; 14: 7-12.
- Schreffler RT, Schreffler AJ, Wittler RR. Treatment of cerebrospinal fluid shunt infections: a decision analysis. Pediatr Infect Dis J 2002; 21: 632-6.
- Kim BN, Peleg AY, Lodise TP et al. Management of meningitis due to antibiotic-resistant Acinetobacter species. Lancet Infect Dis 2009; 9: 245-55.
- Pfausler B, Spiss H, Beer R et al. Treatment of staphylococcal ventriculitis associated with external cerebrospinal fluid drains: a prospective randomized trial of intravenous compared with intraventricular vancomycin therapy. J Neurosurg 2003; 98: 1040-4.
- Beller AJ, Sahar A, Praiss I. Brain abscess. Review of 89 cases over a period of 30 years. J Neurol Neurosurg Psychiatry 1973; 36: 757-68.
- Berlit P, Fedel C, Tornow K, Schmiedek P. [Bacterial brain abscess--experiences with 67 patients]. Fortschr Neurol Psychiatr 1996; 64: 297-306.
- Carpenter J, Stapleton S, Holliman R. Retrospective analysis of 49 cases of brain abscess and review of the literature. Eur J Clin Microbiol Infect Dis 2007; 26: 1-11.
- Hakan T, Ceran N, Erdem I, Berkman MZ, Goktas P. Bacterial brain abscesses: an evaluation of 96 cases. J Infect 2006; 52: 359-66.
- Tattevin P, Bruneel F, Clair B et al. Bacterial brain abscesses: a retrospective study of 94 patients admitted to an intensive care unit (1980 to 1999). Am J Med 2003; 115: 143-6.
- Smith SJ, Ughratdar I, MacArthur DC. Never go to sleep on undrained pus: a retrospective review of surgery for intraparenchymal cerebral abscess. Br J Neurosurg 2009; 23: 412-7.
- Al Masalma M, Armougom F, Scheld WM et al. The expansion of the microbiological spectrum of brain abscesses with use of multiple 16S ribosomal DNA sequencing. Clin Infect Dis 2009; 48: 1169-78.
- de Lastours V, Kalamarides M, Leflon V et al. Optimization of bacterial diagnosis yield after needle aspiration in immunocompetent adults with brain abscesses. Neurosurgery 2008; 63: 362-7.
- Cavusoglu H, Kaya RA, Turkmenoglu ON, Colak I, Aydin Y. Brain abscess: analysis of results in a series of 51 patients with a combined surgical and medical approach during an 11-year period. Neurosurg Focus 2008; 24: E9.
- Goodkin HP, Harper MB, Pomeroy SL. Intracerebral abscess in children: historical trends at Children's Hospital Boston. Pediatrics 2004; 113: 1765-70.
- Le Moal G, Landron C, Grollier G et al. Characteristics of brain abscess with isolation of anaerobic bacteria. Scand J Infect Dis 2003; 35: 318-21.
- Sennaroglu L, Sozeri B. Otogenic brain abscess: review of 41 cases. Otolaryngol Head Neck Surg 2000; 123: 751-5.
- Barlas O, Sencer A, Erkan K, Eraksoy H, Sencer S, Bayindir C. Stereotactic surgery in the management of brain abscess. Surg Neurol 1999; 52: 404-10.
- Mamelak AN, Mampalam TJ, Obana WG, Rosenblum ML. Improved management of multiple brain abscesses: a combined surgical and medical approach. Neurosurgery 1995; 36: 76-85.
- O'Donoghue MA, Green HT, Shaw MD. Cerebral abscess on Merseyside 1980-1988. J Infect 1992; 25: 163-72.
- Tekkok IH, Erbengi A. Management of brain abscess in children: review of 130 cases over a period of 21 years. Childs Nerv Syst 1992; 8: 411-6.
- Renier D, Flandin C, Hirsch E, Hirsch JF. Brain abscesses in neonates. A study of 30 cases. J Neurosurg 1988; 69: 877-82.
- Chun CH, Johnson JD, Hofstetter M, Raff MJ. Brain abscess. A study of 45 consecutive cases. Medicine (Baltimore) 1986; 65: 415-31.
- Brook I. Bacteriology of intracranial abscess in children. J Neurosurg 1981; 54: 484-8.
- Shahzad K, Hamid MH, Khan MA, Malik N, Maqbool S. Brain abscess in children. J Coll Physicians Surg Pak 2005; 15: 609-11.
- de Louvois, ., Gortavai P, Hurley R. Bacteriology of abscesses of the central nervous system: a multicentre prospective study. Br Med J 1977; 2: 981-4.
- Jansson AK, Enblad P, Sjolin J. Efficacy and safety of cefotaxime in combination with metronidazole for empirical treatment of brain abscess in clinical practice: a retrospective study of 66 consecutive cases. Eur J Clin Microbiol Infect Dis 2004; 23: 7-14.
- Bartt R. Listeria and atypical presentations of Listeria in the central nervous system. Semin Neurol 2000; 20: 361-73.
- Roche M, Humphreys H, Smyth E et al. A twelve-year review of central nervous system bacterial abscesses; presentation and aetiology. Clin Microbiol Infect 2003; 9: 803-9.
- Mampalam TJ, Rosenblum ML. Trends in the management of bacterial brain abscesses: a review of 102 cases over 17 years. Neurosurgery 1988; 23: 451-8.
- Bagdatoglu H, Ildan F, Cetinalp E et al. The clinical presentation of intracranial abscesses. A study of seventy-eight cases. J Neurosurg Sci 1992; 36: 139-43.
- Miller ES, Dias PS, Uttley D. CT scanning in the management of intracranial abscess: a review of 100 cases. Br J Neurosurg 1988; 2: 439-46.
- Tonon E, Scotton PG, Gallucci M, Vaglia A. Brain abscess: clinical aspects of 100 patients. Int J Infect Dis 2006; 10: 103-9.
- Gomez J, Garcia-Vazquez E, Martinez PM et al. [Brain abscess. The experience of 30 years]. Med Clin (Barc ) 2008; 130: 736-9.
- Lunardi P, Acqui M, Ferrante L, Mastronardi L, Fortuna A. Non-traumatic brain abscess. Neurosurg Rev 1993; 16: 189-96.
- Nicolosi A, Hauser WA, Musicco M, Kurland LT. Incidence and prognosis of brain abscess in a defined population: Olmsted County, Minnesota, 1935-1981. Neuroepidemiology 1991; 10: 122-31.
- Richards J, Sisson PR, Hickman JE, Ingham HR, Selkon JB. Microbiology, chemotherapy and mortality of brain abscess in Newcastle-upon-Tyne between 1979 and 1988. Scand J Infect Dis 1990; 22: 511-8.
- Svanteson B, Nordstrom CH, Rausing A. Non-traumatic brain abscess. Epidemiology, clinical symptoms and therapeutic results. Acta Neurochir (Wien ) 1988; 94: 57-65.
- Danziger A, Price H, Schechter MM. An analysis of 113 intracranial infections. Neuroradiology 1980; 19: 31-4.
- Hilmani S, Riyahi S, Ibahioin K, Naja A, El KA, El AA. [Brain abscess (80 cases)]. Neurochirurgie 2009; 55: 40-4.
- Morgan H, Wood MW, Murphey F. Experience with 88 consecutive cases of brain abscess. J Neurosurg 1973; 38: 698-704.
- Carey ME, Chou SN, French LA. Long-term neurological residua in patients surviving brain abscess with surgery. J Neurosurg 1971; 34: 652-6.
- Rish BL, Caveness WF, Dillon JD, Kistler JP, Mohr JP, Weiss GH. Analysis of brain abscess after penetrating craniocerebral injuries in Vietnam. Neurosurgery 1981; 9: 535-41.
- Gruszkiewicz J, Doron Y, Peyser E, Borovich B, Schachter J, Front D. Brain abscess and its surgical management. Surg Neurol 1982; 18: 7-17.
- Bradley PJ, Manning KP, Shaw MD. Brain abscess secondary to otitis media. J Laryngol Otol 1984; 98: 1185-91.
- Ersahin Y, Mutluer S, Guzelbag E. Brain abscess in infants and children. Childs Nerv Syst 1994; 10: 1859.
- Schliamser SE, Backman K, Norrby SR. Intracranial abscesses in adults: an analysis of 54 consecutive cases. Scand J Infect Dis 1988; 20: 1-9.
- Mathisen GE, Meyer RD, George WL, Citron DM, Finegold SM. Brain abscess and cerebritis. Rev Infect Dis 1984; 6 Suppl 1: S101-S106.
- Shaw MD, Russell JA. Cerebellar abscess. A review of 47 cases. J Neurol Neurosurg Psychiatry 1975; 38: 429-35.
- Nielsen H. Cerebral abscess in children. Neuropediatrics 1983; 14: 76-80.
- Hirsch JF, Roux FX, Sainte-Rose C, Renier D, Pierre-Kahn A. Brain abscess in childhood. A study of 34 cases treated by puncture and antibiotics. Childs Brain 1983; 10: 251-65.
- Moss SD, McLone DG, Arditi M, Yogev R. Pediatric cerebral abscess. Pediatr Neurosci 1988; 14: 291-6.
- Fischer EG, McLennan JE, Suzuki Y. Cerebral abscess in children. Am J Dis Child 1981; 135: 746-9.
- Dohrmann PJ, Elrick WL. Observations on brain abscess. Review of 28 cases. Med J Aust 1982; 2: 81-3.
- Sharma R, Mohandas K, Cooke RP. Intracranial abscesses: changes in epidemiology and management over five decades in Merseyside. Infection 2009; 37: 39-43.
- van Alphen HA, Dreissen JJ. Brain abscess and subdural empyema. Factors influencing mortality and results of various surgical techniques. J Neurol Neurosurg Psychiatry 1976; 39: 481-90.
- Al MM, Armougom F, Scheld WM et al. The expansion of the microbiological spectrum of brain abscesses with use of multiple 16S ribosomal DNA sequencing. Clin Infect Dis 2009; 48: 1169-78.
- de LJ, Gortvai P, Hurley R. Antibiotic treatment of abscesses of the central nervous system. Br Med J 1977; 2: 985-7.
- Mayhall CG, Archer NH, Lamb VA et al. Ventriculostomy-related infections. A prospective epidemiologic study. N Engl J Med 1984; 310: 553-9.
- Stenager E, Gerner-Smidt P, Kock-Jensen C. Ventriculostomy-related infections--an epidemiological study. Acta Neurochir (Wien ) 1986; 83: 20-3.
- Ohrstrom JK, Skou JK, Ejlertsen T, Kosteljanetz M. Infected ventriculostomy: bacteriology and treatment. Acta Neurochir (Wien ) 1989; 100: 67-9.
- Coplin WM, Avellino AM, Kim DK, Winn HR, Grady MS. Bacterial meningitis associated with lumbar drains: a retrospective cohort study. J Neurol Neurosurg Psychiatry 1999; 67: 468-73.
- Lyke KE, Obasanjo OO, Williams MA, O'Brien M, Chotani R, Perl TM. Ventriculitis complicating use of intraventricular catheters in adult neurosurgical patients. Clin Infect Dis 2001; 33: 2028-33.
- Wong GK, Poon WS, Wai S, Yu LM, Lyon D, Lam JM. Failure of regular external ventricular drain exchange to reduce cerebrospinal fluid infection: result of a randomised controlled trial. J Neurol Neurosurg Psychiatry 2002; 73: 759-61.
- Pfisterer W, Muhlbauer M, Czech T, Reinprecht A. Early diagnosis of external ventricular drainage infection: results of a prospective study. J Neurol Neurosurg Psychiatry 2003; 74: 929-32.
- Park P, Garton HJ, Kocan MJ, Thompson BG. Risk of infection with prolonged ventricular catheterization. Neurosurgery 2004; 55: 594-9.
- Arabi Y, Memish ZA, Balkhy HH et al. Ventriculostomy-associated infections: incidence and risk factors. Am J Infect Control 2005; 33: 137-43.
- Leverstein-van Hall MA, Hopmans TE, van der Sprenkel JW et al. A bundle approach to reduce the incidence of external ventricular and lumbar drain-related infections. J Neurosurg 2010; 112: 345-53.
- Schade RP, Schinkel J, Visser LG, Van Dijk JM, Voormolen JH, Kuijper EJ. Bacterial meningitis caused by the use of ventricular or lumbar cerebrospinal fluid catheters. J Neurosurg 2005; 102: 229-34.
- Walters BC, Hoffman HJ, Hendrick EB, Humphreys RP. Cerebrospinal fluid shunt infection. Influences on initial management and subsequent outcome. J Neurosurg 1984; 60: 1014-21.
- Filka J, Huttova M, Tuharsky J, Sagat T, Kralinsky K, Krcmery V, Jr. Nosocomial meningitis in children after ventriculoperitoneal shunt insertion. Acta Paediatr 1999; 88: 576-8.
- Kestle JR, Garton HJ, Whitehead WE et al. Management of shunt infections: a multicenter pilot study. J Neurosurg 2006; 105: 177-81.
- Sacar S, Turgut H, Toprak S et al. A retrospective study of central nervous system shunt infections diagnosed in a university hospital during a 4-year period. BMC Infect Dis 2006; 6:43.: 43.
- Aucoin PJ, Kotilainen HR, Gantz NM, Davidson R, Kellogg P, Stone B. Intracranial pressure monitors. Epidemiologic study of risk factors and infections. Am J Med 1986; 80: 369-76.
- Kourbeti IS, Jacobs AV, Koslow M, Karabetsos D, Holzman RS. Risk factors associated with postcraniotomy meningitis. Neurosurgery 2007; 60: 317-25.
- Federico G, Tumbarello M, Spanu T et al. Risk factors and prognostic indicators of bacterial meningitis in a cohort of 3580 postneurosurgical patients. Scand J Infect Dis 2001; 33: 533-7.
- Wang KW, Chang WN, Huang CR et al. Post-neurosurgical nosocomial bacterial meningitis in adults: microbiology, clinical features, and outcomes. J Clin Neurosci 2005; 12: 647-50.
- Zarrouk V, Vassor I, Bert F et al. Evaluation of the management of postoperative aseptic meningitis. Clin Infect Dis 2007; 44: 1555-9.
Verantwoording
Autorisatiedatum en geldigheid
Laatst beoordeeld : 01-01-2012
Laatst geautoriseerd : 01-01-2012
Geplande herbeoordeling :
Algemene gegevens
The Dutch Working Party on Antibiotic Policy (SWAB; Stichting Werkgroep Antibiotica Beleid), established by the Dutch Society for Infectious Diseases (VIZ), the Dutch Society of Medical Microbiology (NVMM) and the Dutch Society for Hospital Pharmacists (NVZA), develops evidence-based guidelines for the use of antibiotics in hospitalized patients in order to optimize the quality of prescribing, thus, contributing to the containment of antimicrobial drug costs and resistance. By means of the development of national guidelines, SWAB offers local antibiotic and formulary committees a guideline for the development of their own, local antibiotic policy. These are the first SWAB guidelines on bacterial central nervous system infections. It is developed according to the Evidence Based Guideline Development method (EBRO; www.cbo.nl). The AGREE criteria
(www.agreecollaboration.org) provided a structured framework both for the development and the assessment of the draft guideline.
Relationship between the SWAB Guidelines and the 2012 Guidelines on Meningitis by the Dutch Society for Neurology (Nederlandse Vereniging voor Neurologie)
The SWAB guidelines cover the antimicrobial therapy in children and adults with bacterial meningitis, brain abscesses and tuberculous meningitis. They do not cover other treatment components of bacterial meningitis, such as corticosteroids, osmotic agents and anticoagulants.2 This is discussed extensively in the 2012 guidelines by the Dutch Society for Neurology (Nederlandse Vereniging voor Neurologie). The Nederlandse Vereniging voor Neurologie guidelines adopted the SWAB guidelines on meningitis to be the treatment part of their meningitis guidelines.
Doel en doelgroep
Core issues on cryptococcal meningitis are extensively discussed in the 2008 SWAB guidelines on fungal infections. Diagnostics for bacterial meningitis are briefly discussed in the introduction, but not systematically reviewed in these guidelines. Encephalitis falls outside the scope of these guidelines.
For this guideline we made a distinction based on the setting in which bacterial meningitis was acquired: community-acquired versus nosocomial. Further, we provide recommendations for empirical antimicrobial therapy for clinical subgroups of bacterial meningitis patients. The choice of initial antimicrobial therapy for these subgroups is based on the bacteria most commonly causing the disease, taking into account the patient’s age and clinical setting, and patterns of antimicrobial susceptibility. After the results of culture and susceptibility testing have become available, antimicrobial therapy can be modified for optimal treatment.
Samenstelling werkgroep
Preparatory Committee: Dr. M.C. Brouwer, Drs. S.G.B. Heckenberg, Dr. G.T.J. van Well (Nederlandse Vereniging voor Kindergeneeskunde), Dr. A. Brouwer (Vereniging voor Infectieziekten), Dr. E.J. Delwel (Nederlandse Vereniging voor Neurochirurgie), Dr. L. Spanjaard (Nederlandse Vereniging voor Medisch Microbiologie), Prof. dr. D. van de Beek (Nederlandse Vereniging voor Neurologie), Prof. dr. J.M. Prins (SWAB).
Methode ontwikkeling
Evidence based
Werkwijze
Twelve key questions were formulated concerning the antibiotic treatment of bacterial central nervous system infections. Using several data sources (see data sources) conclusions were drawn, with their specific level of evidence, according to the CBO grading system adopted by SWAB (Table 1).1
Subsequently, specific recommendations were formulated. Each key question will be answered in a separate chapter.
Table 1a
Methodological quality of individual studies.1
|
Intervention |
Etiology, prognosis |
A1 |
Systematic review of at least two independent A2-level studies |
|
A2 |
Randomised Controlled Trial (RCT) of sufficient methodological quality and power |
Prospective cohort study with sufficient power and with adequate confounding corrections |
B |
Comparative Study lacking the same quality as mentioned at A2 (including patientcontrol and cohort studies) |
Prospective cohort study lacking the same quality as mentioned at A2, retrospective cohort study or patient-control study |
C |
Non-comparative study |
|
D |
Expert opinion |
Table 1b
Level of evidence of conclusions
|
Conclusions based on |
1 |
Study of level A1 or at least two independent studies of level A2 |
2 |
One study of level A2 or at least two independent studies of level B |
3 |
One study of level B or C |
4 |
Expert opinion |
Zoekverantwoording
Zoekacties zijn opvraagbaar. Neem hiervoor contact op met de Richtlijnendatabase.